NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Braveheart Bio, Inc. (BRVE) Stock Analysis

Braveheart Bio, Inc. (BRVE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BRVE

$26.74

+$0.47 (+1.79%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BRVE with… →

BRVE Key Statistics

As of Sep 4, 2026
Trading
Open
$25.81
Previous Close
$26.27
Day's Range
25.39–27.48
52-Week Range
24.31–32.00
Volume
272.10K
Valuation
Market Cap
$1.89B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.91
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
70.65M
Dividend and dates
Avg Volume
501.36K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BRVE Valuation vs Biotechnology Median

Median of 656 stocks
MetricBRVEBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Braveheart Bio, Inc. (BRVE) at $1.89B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 30 employees.

BRVE last closed at $26.74 on September 4, 2026. That is +$0.47 (+1.79%) against the previous close. The 52-week range on file runs from $24.31 to $32.00. The latest close sits 10% above that 52-week low.

Financial Health

Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.91.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Growth & Income

The record shows no dividend for BRVE.

2026 is still running; the price is −10.27% year to date.

Peer Comparison

Braveheart Bio, Inc. (BRVE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Braveheart Bio, Inc. BRVE $1.89B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Braveheart Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Braveheart Bio, Inc.

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

Visit website →